Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1314 in Moderate to Severe Plaque Psoriasis
NCT04121143Phase 2Suspended
- Sponsor
- Hengrui
- Start
- Nov 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vunakizumab in plaque psoriasis (4 arms), sponsored by Hengrui. Primary endpoint: Proportion of subjects reaching PASI 75 response at 16 weeks. Started Nov 2019; status: suspended.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04121143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121143.